Immunotherapy

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

Abstract

The central nervous system (CNS) has been referred as an immune privilege, in which local immune responses are restricted (Hailer et al., 1998; Cohen and Schwartz, 1999; Neumann, 2000; Pachter et al., 2003; Villoslada and Genain, 2004; Hatterer et al., 2005). Unlike most peripheral tissues, the CNS functions through a network of post mitotic cells (neurons) that are incapable of regeneration and hence any immune activity might interfere with cell function. CNS is vulnerable to damage that might be caused by the very means that the immune system uses to defend peripheral tissues from pathogens. Consequently, immune privilege in the CNS has been viewed as an evolutionary adaptation developed to protect the intricate neuronal networks of the CNS from incursion by the immune system (Lotan and Schwartz, 1994; Lotan et al., 1994).

Original languageEnglish
Title of host publicationNeuroimmune Pharmacology
PublisherSpringer US
Pages621-630
Number of pages10
ISBN (Print)9780387725727
DOIs
StatePublished - 2008

Keywords

  • Adaptive immunity
  • Copolymer-1 (Copaxone or glatiramer acetate)
  • Immune boost
  • Immune modulation
  • Immune suppression
  • Mucosal tolerance
  • Nasal tolerance
  • Oral tolerance
  • T cell vaccination
  • Vaccination

Fingerprint

Dive into the research topics of 'Immunotherapy'. Together they form a unique fingerprint.

Cite this